Inflammatory skin diseases are common and associated with challenging physical symptoms, psychosocial burden, and systemic comorbidities. Recent scientific advances have improved our understanding of inflammatory skin diseases and led to many efficacious, FDA-approved treatment options. However, not all treatments are approved in children and questions remain surrounding long-term effects of diseases and treatments.
Goals of the Inflammatory Skin Disease Working Group are to define and address unmet research needs in inflammatory skin diseases, to discover new therapies, and to advance our understanding of biomarkers, genetic influences, and disease co-morbidities. PeDRA’s Inflammatory Skin Disease Working Group is divided into five overlapping subgroups:
- Psoriasis, chaired by Amy Paller, MD of Northwestern University, Kelly Cordoro, MD of UCSF, and Kristi Holland, MD of MCW
- Atopic dermatitis, chaired by Wynnis Tom, MD and Larry Eichenfield, MD of UCSD
- Connective tissue and autoinflammatory disorders, chaired by Yvonne Chiu, MD of MCW
- Acne and hidradenitis, chaired by Albert Yan, MD of CHOP
- Hair, nails, and special sites, chaired by Leslie Castelo-Soccio, MD, PhD of CHOP and Nanette Silverberg, MD of Mt. Sinai
Contact us if you’re interested in getting involved!
Putterman, Elana, et al. “Severity of disease and quality of life in parents of children with alopecia areata, totalis, and universalis: a prospective, cross-sectional study.” Journal of the American Academy of Dermatology (2019)
Totri, Christine R., et al. “Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey.” Journal of the American Academy of Dermatology (2017)